Saturday, May 15

Novavax expands COVID-19 vaccine review to involve young children aged 12 to 17

Novavax expands COVID-19 vaccine review to involve young children aged 12 to 17


Novavax Inc said on Monday it had expanded the late-phase research tests its COVID-19 vaccine applicant to include things like up to 3,000 adolescents aged 12 to 17.

Rivals Moderna Inc and Pfizer Inc are also tests their COVID-19 vaccines in more youthful age groups. Moderna’s vaccine is approved for emergency use in the United States in adults aged 18 or higher than, while Pfizer’s shot is authorized for use in men and women aged 16 and earlier mentioned.

Novavax is envisioned to report details from its ongoing massive, late-stage examine in the United States and Mexico for the duration of the 2nd quarter of this yr.

The firm claimed the demo, to be executed across up to 75 web-sites in the United States, will test two doses of its vaccine prospect specified 21-days aside.

Subscribe to Mint Newsletters

* Enter a valid e-mail

* Thank you for subscribing to our e-newsletter.



Source (important)